The Digital Source For China's Tech Innovation Since 2000

Search
Close this search box.

Anti-cancer Vaccine Approved For Research In Shanghai

November 24, 2004
Science

The first Chinese-developed cancer vaccine that was patented abroad has now received permission from the State Food and Drug Administration for clinical tests in Shanghai. The vaccine specifically aims at eradicating liver cancer cells from infected patients.

The No. 2 Medical University of the Chinese People's Liberation Army has worked on the vaccine in collaboration with a Shanghai laboratory that deals with animal cell engineering.

Data from the Ministry of Health showed that the death rate from malignant cancer tumors grew by 29% percent between the1970s and the 1990s in China.

Tags: army | China | Chinese | data | drug | education | food | health | medical | medicine | military | Ministry of Health | People's Liberation Army | PLA | research | Shanghai | State Food and Drug Administration | university | Vaccine

Other Related News:

CODM Global vs Chinese vs Garena Call of Duty Mobile Activision vs Tencent vs Garena PK

May 4, 2022

‘you don’t need to think lower’: China matchmaking app helps improve understanding LGBT problem

October 31, 2021

Diablo Immortal’s Chinese release may be in jeopardy after NetEase employee criticized Xi Jinping

June 27, 2022

Why Taiwan Semiconductor Manufacturing Company Limited Stock Might Make Sense If Bought Today

July 28, 2021

The Observer view on the war in Ukraine, one year on: an even more dangerous phase may await

February 19, 2023

Wealthsource Partners LLC Purchases 9,180 Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) WKRB News

August 7, 2022

In Beijing, French business community welcomes Macron's overtures

April 6, 2023

China Seeks to Tax Bitcoin Exchanges Despite Recent Crypto Ban

October 21, 2021

Beijing prosecutor filed proceedings against Tencent over WeChat’s “youth mode”

August 7, 2021
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
© 2023 ChinaTechNews.com. A Service of Asia Media Network.
Twitter